Lead Program in Hemophilia B Be Biopharma's lead program in Hemophilia B, BE-101, is positioned as a prominent offering, with an IND filing anticipated in mid-2024. This presents a significant sales opportunity to engage healthcare providers and organizations involved in Hemophilia treatment and research.
Strategic Financial Backing With recent investments totaling $130 million in Series B funding, Be Biopharma showcases strong financial health and growth potential. This funding signifies a readiness for partnerships, collaborations, and potential commercial initiatives, providing a ripe landscape for sales engagements.
Key Appointments for Growth Appointments of key personnel like John Mayfield as Chief Business Officer and Dr. Gillis to the Board of Directors position Be Biopharma for strategic growth. Leveraging these leadership additions can open doors for partnerships, acquisitions, and business development opportunities.
B Cell Medicines Innovation Be Biopharma's focus on pioneering Engineered B Cell Medicines (BCMs) for genetic diseases and cancer treatment presents a unique value proposition in the biotechnology sector. This innovation sets the stage for engaging with healthcare providers seeking groundbreaking therapeutic approaches.
Strategic Investor Support The backing of leading investors like Arch Venture Partners highlights confidence in Be Biopharma's vision and capabilities. Leveraging this investor support can be instrumental in driving strategic sales opportunities, collaborations, and market positioning discussions.
93K
$1B
38K$1B
87K$1B
103K$1B
102K$1B
73K$1B
54K$1B
8.1K$1B
78K$1B
93K$1B
36K$1BBe Biopharma uses 8 technology products and services including Cloudflare CDN, Google Cloud, Popper, and more. Explore Be Biopharma's tech stack below.
| Be Biopharma Email Formats | Percentage |
| FLast@be.bio | 87% |
| First@be.bio | 7% |
| First.Last@be.bio | 5% |
| FL@be.bio | 1% |
Biotechnology ResearchMassachusetts, United States51-200 Employees
Be Bio is pioneering Engineered B Cell Medicines (BCMs) to dramatically improve the lives of patients who are living with Hemophilia B and other genetic diseases, cancer, and other serious conditions. With eyes locked on the patient, our team of purpose-driven scientists, technologists, manufacturing experts and business builders collaborate to create a bold new class of cell therapies.
Company Overview
Media & News
Funding & FinancialsBe Biopharma has raised a total of $130M of funding over 2 rounds. Their latest funding round was raised on Apr 14, 2022 in the amount of $130M.
Be Biopharma's revenue is in the range of $10M$50M
Funding & FinancialsBe Biopharma has raised a total of $130M of funding over 2 rounds. Their latest funding round was raised on Apr 14, 2022 in the amount of $130M.
Be Biopharma's revenue is in the range of $10M$50M
1-888-653-2347 
support@leadiq.com